All In Biotech

Drug Trial Radar · NCT01472185

Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Oct 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 465 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

465

Actual

Start

Nov 2011

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when given as monotherapy on glycemic control in subjects with type 2 diabetes mellitus (T2DM) who were inadequately controlled with diet and exercise alone and who are treatment naive to antihyperglycemic therapy or have not received antihyperglycemic therapy in the 90 days (or thiazolidinediones \[TZDs\] for at least 24 weeks) prior to screening, and to characterize the relationship between HbA1c reduction and other glycemic parameters in subjects with T2DM.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • RanolazineDrug

    Ranolazine tablets administered orally twice daily.

  • PlaceboDrug

    Placebo to match ranolazine administered orally twice daily.

  • DietBehavioral

    Participants are instructed to continue the diet regimen prescribed by their physician.

  • ExerciseBehavioral

    Participants are instructed to continue the exercise regimen prescribed by their physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24Time frame: Baseline; Week 24

Locations

159 sites in 10 countries. Site status is shown where the registry gives one.

  • Thunderbird Internal Medicine/Clinical Research Advantage

    Glendale, Arizona

  • Central Phoenix Medical Clinic

    Phoenix, Arizona

  • Desert Sun Clinical Research, LLC

    Tucson, Arizona

  • Eclipse Clinical Research

    Tucson, Arizona

  • North Central Arkansas Medical Associates

    Mountain Home, Arkansas

  • Paul W. Davis, MD, Private Practice

    Pine Bluff, Arkansas

  • Southland Clinical Research Center, Inc.

    Fountain Valley, California

  • Global Research Management

    Glendale, California

  • National Research Institute

    Los Angeles, California

  • Spectrum Clinical Research Institute, Inc

    Moreno Valley, California

  • Sacramento Heart and Vascular Medical Associates

    Sacramento, California

  • Clearview Medical Research LLC

    Santa Clarita, California

  • Infosphere Clinical Research

    West Hills, California

  • Boca Raton Clinical Research Associates, Inc

    Boca Raton, Florida

  • PAB Clinical Research

    Brandon, Florida

  • Florida Research Network, LLC

    Gainesville, Florida

  • A G A Clinical Trials

    Hialeah, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Baptist Diabetes Associates

    Miami, Florida

  • NextPhase Clinical Trials, Inc.

    Miami Beach, Florida

  • Precision Research Organization

    Miami Lakes, Florida

  • Suncoast Clinical Research

    New Port Richey, Florida

  • Florida Institute for Clinical Research LLC

    Orlando, Florida

  • Regenerate Clinical Trials

    South Miami, Florida

  • Synergy Therapeutic Partners

    Atlanta, Georgia

  • CTL Research

    Eagle, Idaho

  • Cedar-Crosse Research Center

    Chicago, Illinois

  • LaPorte County Institute for Clinical Research

    Michigan City, Indiana

  • Clinical Trials Management, LLC

    Metairie, Louisiana

  • MD Medical Research

    Oxon Hill, Maryland

  • IRC Clinics, Inc

    Towson, Maryland

  • Associated Internal Medicine Specialists, P.C.

    Battle Creek, Michigan

  • Albuquerque Clinical Trials

    Albuquerque, New Mexico

  • University of New Mexico Clinical and Translational Science Center

    Albuquerque, New Mexico

  • Clinical Research Solution

    New York, New York

  • PMG Research of Charlotte

    Charlotte, North Carolina

  • PharmQuest

    Greensboro, North Carolina

  • PMG Research of Salisbury

    Salisbury, North Carolina

  • Clinical Inquest Center, Ltd.

    Beavercreek, Ohio

  • Infinity Research Group, LLC

    Oklahoma City, Oklahoma

Showing 40 of 159 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.